Denna sida på svenska

Maria Liljefors

Associated

Visiting address : Byggnad Z1:01, Karolinska Universitetssjukhuset Solna 171 76 Stockholm, Sweden
Postal address : Department of Oncology-Pathology (OnkPat), K7, Research Group Mellstedt, Håkan, Radiumhemmet, Karolinska Universitetssjukhuset Solna 171 76 Stockholm, Sweden
Delivery address : Byggnad R8:01, Karolinska Universitetssjukhuset Solna 171 76 Stockholm, Sweden

Publications

A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer
Ullenhag Gj, Rossmann E, Liljefors M
PloS one 2015;10(4):e0121197-

Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
Staff C, Mozaffari F, Frödin Je, Mellstedt H, Liljefors M
International journal of oncology 2014;45(3):1293-303

Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein
Staff C, Magnusson Cgm, Hojjat-farsangi M, Mosolits S, Liljefors M, Frodin Je, et al
JOURNAL OF CLINICAL IMMUNOLOGY 2012;32(4):855-65

A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients
Staff C, Mozaffari F, Haller Bk, Wahren B, Liljefors M
VACCINE 2011;29(39):6817-22

Fc gamma R polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment
Wang By, Kokhaei P, Mellstedt H, Liljefors M
INTERNATIONAL JOURNAL OF ONCOLOGY 2010;37(6):1599-606

TELOMERASE-PEPTIDE VACCINE TOGETHER WITH GEMCITABINE IN ADVANCED PANCREATIC CANCER PATIENTS
Staff Ceb, Mozaffari Fm, Liljefors M, Mosolits S, Frodin J, Choudhury A, et al
ANNALS OF ONCOLOGY 2010;:26-26

Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity
Liljefors M, Nilsson B, Mellstedt H, Mellstedt H, Frodin Je
CANCER IMMUNOLOGY IMMUNOTHERAPY 2008;57(3):379-88

Quantitative assessment of the subepithelial collagen band does not increase the accuracy of diagnosis of collagenous colitis
Rubio Ca, Orrego A, Hoog A, Porwitz A, F'etersson F, Elmberger G, et al
AMERICAN JOURNAL OF CLINICAL PATHOLOGY 2008;130(3):375-81

Repeated bone marrow analyses for cytokeratin positive cells in patients with colorectal carcinoma.
Liljefors M, Frodin Je, Porwit A, Ragnhammar P, Mellstedt H, Shetye J
ANNALS OF ONCOLOGY 2007;:49-49

Continued treatment with anti-EpCAM mouse monoclonal antibody in spite of previous allergic reactions in patients with metastatic colorectal carcinoma
Liljefors M, Frodin Je, Mellstedt H
ANNALS OF ONCOLOGY 2006;:48-48

Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma
Liljefors M, Nilsson B, Fagerberg J, Ragnhammar P, Mellstedt H, Frodin Je
INTERNATIONAL JOURNAL OF ONCOLOGY 2005;26(6):1581-9

Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma
Liljefors M, Ragnhammar P, Nilsson B, Ullenhag G, Mellstedt H, Frodin Je
INTERNATIONAL JOURNAL OF ONCOLOGY 2004;25(3):703-11

Clinical effects of chimeric anti-EpCAM monoclonal antibody (cMAb17-1A) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with colony-stimulating factor (GM-CSF) in patients with metastatic colorectal carcinoma (MCRC)
Liljefors M, Fagerberg J, Nilsson B, Ragnhammar P, Mellstedt H, Frodin Je
ANNALS OF ONCOLOGY 2004;:84-84

Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients
Shetye Jd, Liljefors Ml, Emdin So, Frodin Je, Strigard K, Mellstedt Ht, et al
ANTICANCER RESEARCH 2004;24(4):2375-83

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A
Liljefors M, Nilsson B, Skog Alh, Ragnhammar P, Mellstedt H, Frodin Je
INTERNATIONAL JOURNAL OF CANCER 2003;105(5):717-23

MAb17-1A and Cytokines for the treatment of patients with colorectal carcinoma
Frodin Je, Fagerberg J, Skog Alh, Liljefors M, Ragnhammar P, Mellstedt H
HYBRIDOMA AND HYBRIDOMICS 2002;21(2):99-101

Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma
Mellstedt H, Fagerberg J, Frodin Je, Hjelm-skog Al, Liljefors M, Markovic K, et al
COLORECTAL CANCER: NEW ASPECTS OF MOLECULAR BIOLOGY AND IMMUNOLOGY AND THEIR CLINICAL APPLICATIONS 2000;:254-61

Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors
Mellstedt H, Fagerberg J, Frödin Je, Henriksson L, Hjelm-skoog Al, Liljefors M, et al
Current opinion in hematology 1999;6(3):169-75

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma
Skog Alh, Ragnhammar P, Fagerberg J, Frodin Je, Goldinger M, Koldestam H, et al
CANCER IMMUNOLOGY IMMUNOTHERAPY 1999;48(8):463-70

Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF
Wadhwa M, Skog Alh, Bird C, Ragnhammar P, Lilljefors M, Gaines-das R, et al
CLINICAL CANCER RESEARCH 1999;5(6):1353-61

Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor
Shetye J, Ragnhammar P, Liljefors M, Christensson B, Frodin Je, Biberfeld P, et al
CLINICAL CANCER RESEARCH 1998;4(8):1921-9

Epithelial cells in the bone marrow (BM) of colorectal carcinoma (CRC) patients: A tool to monitor immunotherapy?
Liljefors M, Frodin Je, Shetye J, Porwit A, Ragnhammar P, Samanci A, et al
EUROPEAN JOURNAL OF CANCER 1997;:386-386

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A
Fagerberg J, Ragnhammar P, Liljefors M, Hjelm Al, Mellstedt H, Frodin Je
CANCER IMMUNOLOGY IMMUNOTHERAPY 1996;42(2):81-7

Show all publications